D. E. Shaw & Co., Inc. Intellia Therapeutics, Inc. Transaction History

D. E. Shaw & Co., Inc.

$100 Billion
Q1 2025

A detailed history of D. E. Shaw & Co., Inc. transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 35,100 shares of NTLA stock, worth $339,066. This represents 0.0% of its overall portfolio holdings.

Number of Shares

35,100

Previous 64,500 45.58%

Holding current value

$339,066

Previous $752,000 66.89%

% of portfolio

0.0%

Previous 0.0%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$7.11 - $12.8 $8,439 - $15,193	-1,187 Reduced 3.53%	32,396 $230,000
Q4 2024 Feb 14, 2025	BUY	$11.41 - $21.09 $243,067 - $449,280	21,303 Added 173.48%	33,583 $391,000
Q3 2024 Nov 14, 2024	BUY	$19.72 - $27.36 $242,161 - $335,980	12,280 New	12,280 $252,000
Q4 2022 Feb 14, 2023	SELL	$33.21 - $62.69 $1.21 Million - $2.28 Million	-36,419 Reduced 70.62%	15,152 $528,000
Q3 2022 Nov 14, 2022	SELL	$53.92 - $71.7 $20.2 Million - $26.9 Million	-374,779 Reduced 87.9%	51,571 $2.89 Million
Q2 2022 Aug 15, 2022	BUY	$38.49 - $76.21 $8 Million - $15.8 Million	207,941 Added 95.21%	426,350 $22.1 Million
Q1 2022 May 16, 2022	BUY	$58.27 - $118.99 $12.6 Million - $25.7 Million	215,775 Added 8191.91%	218,409 $15.9 Million
Q4 2021 Feb 14, 2022	SELL	$100.76 - $138.36 $745,422 - $1.02 Million	-7,398 Reduced 73.74%	2,634 $311,000
Q3 2021 Nov 15, 2021	SELL	$132.37 - $176.78 $13.9 Million - $18.6 Million	-104,960 Reduced 91.28%	10,032 $1.35 Million
Q2 2021 Aug 16, 2021	SELL	$60.88 - $161.91 $17.6 Million - $46.7 Million	-288,728 Reduced 71.52%	114,992 $18.6 Million
Q1 2021 May 17, 2021	BUY	$46.59 - $83.68 $1.97 Million - $3.54 Million	42,349 Added 11.72%	403,720 $32.4 Million
Q4 2020 Feb 16, 2021	BUY	$18.83 - $63.53 $3.57 Million - $12 Million	189,402 Added 110.14%	361,371 $19.7 Million
Q3 2020 Nov 16, 2020	SELL	$17.47 - $24.93 $392,935 - $560,725	-22,492 Reduced 11.57%	171,969 $3.42 Million
Q2 2020 Aug 14, 2020	BUY	$11.14 - $22.87 $2.17 Million - $4.45 Million	194,461 New	194,461 $4.09 Million
Q1 2020 May 15, 2020	SELL	$9.44 - $15.58 $119,180 - $196,697	-12,625 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$10.43 - $17.67 $131,678 - $223,083	12,625 New	12,625 $185,000

Others Institutions Holding NTLA

# of Institutions

344

Shares Held

98.4M

Call Options Held

784K

Put Options Held

713K

View Full List

About Intellia Therapeutics, Inc.

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $734M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

More about NTLA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account